Systemic immune and metabolomic responses to oral hyaluronic acid in a randomized placebo-controlled clinical study

Oral hyaluronan (HA) supplementation has shown clinical benefits, but its systemic effects remain insufficiently characterized. We focused on the systemic effects of oral HA. (1.8 MDa) at 60 mg/day (SH60), 120 mg/day (SH120), or placebo for 12 weeks in 150 healthy donors. Within this randomized, double-blind, placebo-controlled study, plasma samples were analyzed to assess changes in immune and metabolic markers, as well as alterations in lipid metabolism, using high-quality, untargeted omics approaches with high information depth. The SH120 group significantly reduced pro-inflammatory markers, including CRP, IL-1b, and precursor of inflammatory mediators such as arachidonic acid, compared with placebo. Together with selective modulation in metabolic biomarkers, including fetuin-A, adipsin, mannopyranosyl tryptophan, 1,16-hexadecanedioic acid, and 3-hydroxydecanoic acid, support the hypothesis that oral HA may promote an immune homeostasis and a “metabolically healthy” profile, exerting protective effects even in otherwise healthy individuals. Correlations between plasma markers and previously reported skin outcomes were generally weak, suggesting that modulation of systemic biomarkers can explain only partially the cutaneous effects of supplementation. Overall, oral HA was associated with selective changes in plasma biomarkers in healthy adults, which should be considered when evaluating the mechanisms underlying its clinical effects. Trial registration ClinicalTrials.gov, NCT07065110 (retrospectively registered on 15 Jul 2025) EFSA (European Food Safety Authority) registry EFSA202400027979 (prospectively filed on 06 Jun 2024).

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-21
DOI
https://doi.org/10.1038/s41598-026-80937-9
Primary Topic
Proteoglycans and glycosaminoglycans research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Systemic immune and metabolomic responses to oral hyaluronic acid in a randomized placebo-controlled clinical study

Romana Šínová, Petra Ovesná, Lukáš Kubala, Matěj Šimek et al.
4 links
Scientific Reports
Proteoglycans and glycosaminoglycans research
article

Systemic immune and metabolomic responses to oral hyaluronic acid in a randomized placebo-controlled clinical study

Romana Šínová, Petra Ovesná, Lukáš Kubala, Matěj Šimek, Vratislav Berka
article en

Abstract

Oral hyaluronan (HA) supplementation has shown clinical benefits, but its systemic effects remain insufficiently characterized. We focused on the systemic effects of oral HA. (1.8 MDa) at 60 mg/day (SH60), 120 mg/day (SH120), or placebo for 12 weeks in 150 healthy donors. Within this randomized, double-blind, placebo-controlled study, plasma samples were analyzed to assess changes in immune and metabolic markers, as well as alterations in lipid metabolism, using high-quality, untargeted omics approaches with high information depth. The SH120 group significantly reduced pro-inflammatory markers, including CRP, IL-1b, and precursor of inflammatory mediators such as arachidonic acid, compared with placebo. Together with selective modulation in metabolic biomarkers, including fetuin-A, adipsin, mannopyranosyl tryptophan, 1,16-hexadecanedioic acid, and 3-hydroxydecanoic acid, support the hypothesis that oral HA may promote an immune homeostasis and a “metabolically healthy” profile, exerting protective effects even in otherwise healthy individuals. Correlations between plasma markers and previously reported skin outcomes were generally weak, suggesting that modulation of systemic biomarkers can explain only partially the cutaneous effects of supplementation. Overall, oral HA was associated with selective changes in plasma biomarkers in healthy adults, which should be considered when evaluating the mechanisms underlying its clinical effects. Trial registration ClinicalTrials.gov, NCT07065110 (retrospectively registered on 15 Jul 2025) EFSA (European Food Safety Authority) registry EFSA202400027979 (prospectively filed on 06 Jun 2024).

Scientific Reports
Masaryk University (CZ), Czech Academy of Sciences, Institute of Biophysics (CZ), International Clinical Research Center, St. Anne's University Hospital Brno (CZ), Contipro (Czechia) (CZ)
Ministerstvo Školství, Mládeže a Tělovýchovy, Grantová Agentura České Republiky
Good health and well-being
Proteoglycans and glycosaminoglycans research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon